Dr. Reddy’s Laboratories reported a 70.21 per cent increase in its consolidated net profit at Rs. 618.42 crore for the third quarter ended December 31, 2013.
The company had posted a consolidated profit of Rs. 363.31 crore in the same period of the previous financial year.
Consolidated net sales rose to Rs. 3,533.76 crore in the quarter under review from Rs. 2,865.16 crore a year earlier, Dr. Reddy’s Laboratories said in a BSE filing.
Revenue from the global generics segment grew to Rs. 2,939.58 crore in the December quarter of 2013 as against Rs. 2,082.77 crore in the corresponding period a year ago, driven by North America, Russia and other emerging markets.
Shares of Dr Reddy’s Laboratories were trading at Rs 2668.15 per scrip during the afternoon trade at BSE, down 0.32 per cent from its previous close.